Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Hangzhou Tigermed Consulting Co., Ltd.
  6. News
  7. Summary
    300347   CNE100001KV8

HANGZHOU TIGERMED CONSULTING CO., LTD.

(300347)
  Report
End-of-day quote Shenzhen Stock Exchange  -  2023-01-19
123.38 CNY   -1.24%
01/19Hangzhou Tigermed Consulting Co., Ltd. acquired Marti Farm d.o.o. za trgovinu i usluge.
CI
01/05Tranche Update on Hangzhou Tigermed Consulting Co., Ltd.'s Equity Buyback Plan announced on February 13, 2022.
CI
2022Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$80.36 From HK$105.58, Keeps at Buy
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Hangzhou Tigermed Consulting Co., Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 31 May 2022

05/25/2022 | 03:33pm EST

Hangzhou Tigermed Consulting Co. Ltd. announced the cash dividend of CNY 5.00000000 per 10 A shares (tax included). The dividend will paid on 31 May 2022 with record date of 30 May 2022 and ex-date is 31 May 2022.


ę S&P Capital IQ 2022
All news about HANGZHOU TIGERMED CONSULTING CO., LTD.
01/19Hangzhou Tigermed Consulting Co., Ltd. acquired Marti Farm d.o.o. za trgovinu i usluge.
CI
01/05Tranche Update on Hangzhou Tigermed Consulting Co., Ltd.'s Equity Buyback Plan announce..
CI
2022Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to HK$80.36 From HK$105.58, ..
MT
2022Nomura Adjusts Hangzhou Tigermed Consulting's Price Target to 116.32 Yuan From 119.66 Y..
MT
2022Tigermed Consulting's Q3 Profit Slumps 22%; Revenue Beats Estimates
MT
2022Hangzhou Tigermed Consulting Co., Ltd. Reports Earnings Results for the Nine Months End..
CI
2022Hangzhou Tigermed Consulting CFO Resigns
MT
2022Hangzhou Tigermed Consulting Co., Ltd. Announces Chief Financial Officer Changes
CI
2022Guangzhou Hipower Pharmaceutical R&D Co.,Ltd announced that it has received funding fro..
CI
2022Tranche Update on Hangzhou Tigermed Consulting Co., Ltd.'s Equity Buyback Plan announce..
CI
More news
Analyst Recommendations on HANGZHOU TIGERMED CONSULTING CO., LTD.
More recommendations
Financials
Sales 2022 7 152 M 1 054 M 1 054 M
Net income 2022 2 173 M 320 M 320 M
Net cash 2022 8 584 M 1 265 M 1 265 M
P/E ratio 2022 43,9x
Yield 2022 0,49%
Capitalization 104 B 15 276 M 15 274 M
EV / Sales 2022 13,3x
EV / Sales 2023 10,3x
Nbr of Employees -
Free-Float 68,4%
Chart HANGZHOU TIGERMED CONSULTING CO., LTD.
Duration : Period :
Hangzhou Tigermed Consulting Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANGZHOU TIGERMED CONSULTING CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 123,38 CNY
Average target price 133,40 CNY
Spread / Average Target 8,12%
EPS Revisions
Managers and Directors
Xiao Chun Cao General Manager & Executive Director
Hao Wu Co-President & Executive Director
Cheng Cheng Yang Chief Financial Officer
Xiao Ping Ye Chairman
Bing Hui Zhang Chairman-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
HANGZHOU TIGERMED CONSULTING CO., LTD.17.73%15 246
MODERNA, INC.7.49%74 239
LONZA GROUP AG17.19%42 748
IQVIA HOLDINGS INC.11.53%42 445
ALNYLAM PHARMACEUTICALS, INC.-3.63%28 492
SEAGEN INC.8.70%25 936